insights_auto
Outlook: 93.3% bullish·0.0% bearish
Go to analysischevron_right
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$121.84
arrow_upward
+0.27%(+0.33) 1D
$121.37
arrow_downward
-0.39% (-0.47)bedtimeAfter hours
Closed: Oct 16, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$122.19
High
$122.44
Low
$120.19
Mkt. cap
13.83B
Avg. vol.
2.42M
Volume
2.08M
P/E ratio
36.41
52-wk high
$122.44
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
Open
$122.19
High
$122.44
Low
$120.19
Mkt. cap
13.83B
Avg. vol.
2.42M
Volume
2.08M
P/E ratio
36.41
52-wk high
$122.44
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
Zacks
·
8 hours ago
5 Stocks to Buy Using the Relative Price Strength Strategy
Zacks
·
10 hours ago
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
Zacks
·
11 hours ago
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Investing.com
·
13 hours ago
H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com